GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

DISEASE CHARACTERISTICS:

* Histologically confirmed malignant recurrent glioma\*, including any of the following:

  * Glioblastoma

    * Glioblastoma multiforme
* Recurrent disease or progressive primary disease
* Surgically accessible tumor for which surgical resection is indicated and has not been previously irradiated
* Prior radiotherapy required
* No prior oncophage therapy or immunotherapy for glioma

PATIENT CHARACTERISTICS:

* Karnofsky performance status 80-100%
* Life expectancy ≥ 8 weeks
* Absolute granulocyte count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Alkaline phosphatase and serum glutamic-pyruvic transaminase (SGPT) \<=2.5 times normal
* Bilirubin \< 1.5 mg/dL
* Blood Urea Nitrogen (BUN) \< 1.5 times normal OR creatinine \< 1.5 times normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective barrier contraception during and for at least 4 weeks after completion of study treatment
* No uncontrolled active infection
* No bleeding diathesis
* No psychiatric or medical situation that would preclude study compliance
* No unstable or severe concurrent medical condition
* No other cancer or concurrent malignancy within the past 5 years except adequately treated nonmetastatic in situ carcinoma of the uterine cervix, nonmetastatic nonmelanoma skin cancer, or in complete remission and off all therapy for that disease
* No systemic autoimmune disease (e.g., Hashimoto's thyroiditis) and/or any history of primary or secondary immunodeficiency

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 2 weeks since prior vincristine
* At least 6 weeks since prior nitrosoureas
* At least 4 weeks since prior temozolomide or other cytotoxic chemotherapy
* At least 4 weeks since prior investigational agents
* At least 1 week since prior noncytotoxic agents
* At least 3 weeks since prior procarbazine
* No radiotherapy within the past 4 weeks